Advertisement

FDA Approves New Antidepressant — Physician’s First Watch

Medical News |
October 2, 2013

FDA Approves New Antidepressant

By Kristin J. Kelley

The FDA has approved vortioxetine (marketed as Brintellix) for adults with major depressive disorder. The drug has several mechanisms of action, including receptor activity modulation and reuptake inhibition, and does not appear to impair psychomotor performance.

Vortioxetine was effective in treating depression in six clinical trials. Additionally, in another study, patients randomized to vortioxetine had driving performances similar to those on placebo.

Like all antidepressants, vortioxetine will carry a boxed warning about the increased risk for suicidality during the early phase of treatment in patients up to age 24. Commonly reported side effects include constipation, nausea, and vomiting. The tablets will be available in 5-, 10-, 15- and 20- mg doses.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement